• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Lumateperone in Bipolar Depression

Lumateperone in Bipolar Depression

January 31, 2022
John C. Raiss, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John C. Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Calabrese JR et al, Am J Psychiatry 2021. Epub ahead of print

STUDY TYPE: Randomized, placebo-controlled trial

In 2019, lumateperone (Caplyta) became the 13th atypical antipsychotic with FDA approval in schizophrenia. Compared to other atypicals, it is relatively well tolerated, with low rates of akathisia and metabolic side effects. On December 20, 2021, the FDA approved the drug for bipolar I and II depression, and here we report on one of the trials that led to that approval.

This large, randomized, placebo-controlled, multi-center trial involved 377 patients with both bipolar I (n = 301) and bipolar II (n = 76) depression. The study was “quadruple blind,” meaning the subjects, providers, investigators, and people administering the rating scales were all blinded to the assigned treatment. The primary outcome measure was the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS). Lumateperone was started and maintained at 42 mg/day and used as monotherapy.

After six weeks, lumateperone outperformed placebo with a medium effect size (0.56) on the primary outcome of change on MADRS. Response (51.1% vs 36.7%, p < 0.001) and remission rates (39.9% vs 33.5%, p < 0.018) were also significantly greater with lumateperone. It was well tolerated, with minimal risk of metabolic, EPS, and prolactin side effects. A post-hoc analysis found greater benefits in bipolar II vs bipolar I depression (effect size of 0.81 vs 0.49) and revealed that a subgroup of patients with mixed features benefited from the medication.

The FDA reviewed two other trials that tested lumateperone in bipolar I and bipolar II depression with a similar design. These have not been published but were made available as a press release. One study was negative (study 401) and the other positive (study 402). Both were large, six-week trials, enrolling 554 and 529 patients. Unlike the Calabrese study, they tested three arms: lumateperone 28 mg, lumateperone 42 mg, and placebo. The positive study tested lumateperone as an adjunct to lithium or valproate and arrived at a small effect size (0.27) for the 42 mg dose and a nonsignificant effect with the 28 mg dose. A fourth trial is underway for unipolar depression with mixed features, a new disorder in DSM-5 that recognizes manic features in depressed patients who do not meet criteria for a bipolar diagnosis.

These trials are unique in their inclusion of bipolar II patients. Among the antipsychotics, only quetiapine and cariprazine have large studies in bipolar II depression, and only quetiapine’s studies were positive.

TCPR’S TAKE
Lumateperone joins quetiapine as the only atypical antipsychotic with evidence in both bipolar I and bipolar II depression. Its main advantage is its favorable tolerability, while disadvantages include cost and the lack of research in the manic and maintenance phases of bipolar disorder.
General Psychiatry
KEYWORDS bipolar-depression bipolar-ii bipolar_disorder lumateperone second-generation-antipsychotics-sgas
    John C. Raiss, MD.

    Talking with Parents About Stimulant Treatment

    More from this author
    www.thecarlatreport.com
    Issue Date: February 1, 2022
    SUBSCRIBE NOW
    Table Of Contents
    An Off-Label Guide to Gabapentin
    MDMA-Assisted Therapy for Severe PTSD
    Lumateperone in Bipolar Depression
    A Novel Treatment for Methamphetamine Use Disorder
    Lybalvi: The Diet Olanzapine
    Raising the Bar in Schizophrenia Treatment
    CME Post-Test - Schizophrenia, TCPR, February 2022
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • shutterstock_2369359177.jpg
      General Psychiatry

      Bipolar Upgrade 7: Social Rhythm Therapy

      Social Rhythm Therapy helps patients regulate their circadian rhythm. It treats bipolar disorder,
      and here we show how to weave it in with medication therapy.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.